16th Annual Scientific Meeting - Heart Failure Society of America
16th Annual Scientific Meeting - Heart Failure Society of America
16th Annual Scientific Meeting - Heart Failure Society of America
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Sept. 10<br />
Monday<br />
AM<br />
Monday<br />
SATELLITE SYMPOSIUM<br />
Monday, September 10<br />
6:45-7:45 AM<br />
Ballroom 6A<br />
Hydralazine and Isosorbide Dinitrate Therapy in<br />
<strong>Heart</strong> <strong>Failure</strong>: Past, Present, and Future<br />
Chair: Javed Butler, Atlanta, GA<br />
6:45 Introduction<br />
Javed Butler, Atlanta, GA<br />
6:50 Nitric Oxide Pathobiology and <strong>Heart</strong> <strong>Failure</strong><br />
Douglas L. Mann, St. Louis, MO<br />
7:00 Evidence Supporting the Benefit <strong>of</strong> H-ISDN in the<br />
Treatment <strong>of</strong> HF<br />
Eldrin F. Lewis, Boston, MA<br />
7:10 Guideline Recommendations and Clinical Use <strong>of</strong> H-ISDN<br />
Gregg C. Fonarow, Los Angeles, CA<br />
7:20 Unanswered Questions and Future Research<br />
Javed Butler, Atlanta, GA<br />
7:35 Panel Discussion<br />
Faculty<br />
OPENING PLENARY SESSION<br />
Monday, September 10<br />
8:00-10:00 AM<br />
Ballrooms 6B and 6C<br />
8:00 Opening and Welcome Remarks<br />
Steven R. Houser, Philadelphia, PA<br />
Lynne Warner Stevenson, Boston, MA<br />
Barbara J. Riegel, Philadelphia, PA<br />
8:10 2012 HFSA Lifetime Achievement Award<br />
Presented by Jay N. Cohn<br />
8:25 Presidential Address<br />
Barry M. Massie, San Francisco, CA<br />
Communication in a New World<br />
Moderators: Lynne W. Stevenson, Boston, MA<br />
Thomas Force, Philadelphia, PA<br />
8:40 Feedback Loops Wired to Change Biology<br />
Thomas Goetz, Princeton, NJ<br />
9:20 Reaching Out for the Words<br />
Billy Collins, Winter Park, FL<br />
Sept. 10<br />
Monday<br />
AM<br />
Monday<br />
Learning Objectives:<br />
1. Describe clinical trial evidence and practice guidelines<br />
supporting the use <strong>of</strong> H-ISDN in patients with heart<br />
failure<br />
2. Describe nitric oxide pathobiology in heart failure<br />
3. Identify potential barriers to the effective use <strong>of</strong> H-ISDN<br />
in patients with heart failure and strategies for addressing<br />
these barriers<br />
4. Describe the role <strong>of</strong> H-ISDN in the treatment <strong>of</strong> nonblacks<br />
and women with HF, pulmonary hypertension, and<br />
acute HF<br />
5. Describe bioequivalence data <strong>of</strong> combination H-ISDN<br />
and generic preparations<br />
6. Discuss ongoing research and quality <strong>of</strong> care initiatives<br />
with H-ISDN<br />
Learning Objective: Describe ways in which communication<br />
at the personal, biological, and technological levels affect<br />
healthcare.<br />
Supported by an educational grant from Arbor<br />
Pharmaceuticals, Inc.<br />
This symposium is not part <strong>of</strong> the scientific program as planned by<br />
the HFSA <strong>Scientific</strong> Program Committee.<br />
40 41
Change language